Surgery versus monitoring for liver cancer that has disappeared
Part of Cancer, Digestive system clinical trials.
This study compares two options for people whose liver cancer has completely disappeared after treatment: having surgery to remove the remaining affected area, or continuing to monitor closely without immediate surgery. It aims to find out which approach helps people live longer and live better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You have liver cancer (hepatocellular carcinoma) that was confirmed by biopsy or by standard imaging.
- You were previously treated with an immunotherapy drug (PD-1 or PD-L1 inhibitor) combined with a targeted or anti-angiogenic drug, with or without local treatments like chemoembolization or radiation.
- Your cancer has completely disappeared on repeat imaging, confirmed 4 to 8 weeks later.
- You are healthy enough for liver surgery, with good liver function and no major heart, lung, or kidney problems.
- You have no cancer spread outside the liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.